post-BMT complications may be influenced not only by T cell dose but by the alloreactive potential of the cells infused. LDA of alloreactive potential was useful in Recipients of marrow from alternative donors (unrelated or HLA-mismatched related donors) have a detecting disparity and in predicting survival or chronic GVHD in recipients of alternative donor TCD marhigher incidence of post-transplant complications compared to recipients of marrow from HLA-identical sibrow grafts. Keywords: bone marrow transplant; cytolytic T lympholings. HLA disparity undetected by routine typing techniques has been suggested as one cause for the increased cytes; helper T lymphocytes; graft-versus-host disease; limiting dilution assay complications observed. Limiting dilution analysis (LDA) of donor-derived, host-reactive T cell precursor frequency prior to transplant has been proposed as a surrogate indicator of underlying HLA disparity which Recipients of alternative donor marrow transplants using might be used to predict transplant outcome and aid in unrelated or family member donors other than HLA-identdonor selection. We compared results of LDA of hostical siblings, have a higher likelihood of post-transplant reactive IL-2 producing helper T lymphocytes (HTLp) complications, particularly graft-versus-host disease and/or cytolytic T lymphocytes (CTLp) in 77 alternative (GVHD) and graft rejection leading to a lower overall surmarrow donor/recipient pairs with transplant outcome vival compared to recipients of grafts from HLA-matched using univariate and multivariate analysis. All donor siblings. 1-3 T lymphocytes are the primary mediators of grafts were depleted ex vivo of mature T cells. Median both graft rejection and graft-versus-host disease and are patient age was 15 years (1-53). Donor selection was highly responsive to most MHC class I and class II antigen based on serologic typing for HLA class I and high resdifferences. 4,5 Depletion of mature T cells from the donor olution oligotyping for HLA-DRB1-DRB5, and HLAgraft reduces the incidence and severity of acute GVHD. DQB1. HLA-A and HLA-B locus antigens were retroHowever, recipients of T cell-depleted alternative donor spectively defined by one dimensional isoelectric focusmarrow are still at higher risk of GVHD than their countering (IEF). Cox proportional hazards regression models parts who receive grafts from HLA-identical siblings.
phocyte precursors (HTLp) in the donor circulation at the Sex male (%) 38 (49) time of transplant. The HTLp assay was designed so as to CMV+ (%) 32 (42) be insensitive to minor histocompatibility antigen differDonor source (%) ences to focus on detection of MHC differences. We looked Related 10 (13) at the ability of both assays to detect HLA disparity and infused. Cox proportional regression analysis was used to у3 7 (9) Type of mismatch (%) develop statistical models to detemine the effect of alloClass I only 20 (26) reactive cell frequencies and dose on transplant outcome. 
Materials and methods
Acute nonlymphocytic leukemia 8 (10) Chronic myelogenous leukemia 25 (32) Patients, preparative regimen, and GVHD prophylaxis Myelodysplastic syndrome 7 (9) Aplastic anemia 10 (13)
A total of 77 donor/recipient pairs were retrospectively Lymphoproliferative 3 (4) studied using peripheral blood mononuclear cells (PBMC) 
years). Pediatric and adult
No. relapsed 18 (27) patients were transplanted for leukemia, aplasia, lymphoAcute GVHD (%) proliferative disorders or immunological deficiency as ate marrow grafts to prevent rejection. All patients received GVHD prophylaxis with cyclosporine from day −1. Tapering over 3-4 months beginning on day 40-50 post-BMT Limiting dilution assays was used for patients not experiencing acute GVHD.
LDA of total clonable T cells contained in the donor marrow was performed before and after T cell depletion as HLA typing and donor selection described. 25 CTLp were determined using a method based on Kaminski et al 27 as previously described. 28 Briefly, Donor selection was based on serologic typing for HLA-A and B locus antigens and high resolution sequence-specific seven concentrations of donor responder PBMC ranging from 5 × 10 4 /well to 2.5 × 10 3 /well in each of 24 replicate oligotyping for HLA-DRB1, -DRB3, -DRB4, -DRB5 and -DQB1 alleles. HLA-A and HLA-B were assessed by one 200 l wells were stimulated with 5 × 10 4 irradiated patient stimulator cells. Twenty-four replicate wells with stimudimensional isoelectric focusing as previously described 11 and included the use in selected cases of carboxypeptidase lators but no responders were plated as the baseline control. An extra 24 wells at the highest responder cell concento help resolve HLA-A and HLA-B locus bands which comigrated on the gels. 26 Differences at HLA-A, -B, -DRB1 tration were tested against donor targets to assess autoreactivity and 24 replicates of donor responders at 5 × 10 4 /well and -DQ unique to the patient were considered as disparities for statistical analysis. The HLA class and number of were stimulated and tested to a third party normal donor to assess the alloreactive potential of the donor cells. antigens mismatched are shown in Table 1 .
Irradiated patient stimulator cells were tested to normal responder cell concentration used (5 × 10 4 cells/well). The third party responders to assess the stimulatory ability of wells were pooled at a concentration of 5 × 10 5 /ml in the patient cells. Cultures were initiated in the absence of medium with 20 U/ml rIL-2 and restimulated with added IL-2 and on days 3-4 and 6-7, 100 l of medium irradiated patient BLCL at a stimulator to responder ratio was removed and replaced with 100 l of medium containof 1:4. The cells were returned to culture for 10-14 days ing 100 Cetus U/ml recombinant IL-2 (kindly provided by with addition of fresh medium containing IL-2 as required Cetus, Emeryville, CA, USA) at a concentration of to keep cell density below 10 6 /ml. After culture the cells 5 U/well. Each Cetus unit of IL-2 activity is equal to 6 were washed free of medium and were tested in 4 h 51 Cr WHO International Units. On day 10 or day 11 cytotoxicity release assays to patient BLCL targets at four effector to was assessed in a 4 h 51 Cr release assay using B lymphoblatarget ratios ranging from 25:1 to 1:1 in the presence and stoid cell line (BLCL) targets. Gamma counter data were absence of HLA-specific monoclonal antibodies. The opticaptured on a spreadsheet to determine the frequency of mal saturating concentration of W6/32 (anti-A, B and C negative wells and to calculate the precursor frequency. were expressed as the highest % of blocking compared to The HTLp LDA was based on the method described by the antibody-free controls. Donor BLCL were included in Theobald et al 29 and has been previously described. 28 each assay to exclude the possibility of the generation of Briefly 24-replicate V-bottomed wells of donor responder EBV-specific CTL during the restimulation phase. PBMC plated at seven concentrations serially two-fold diluted from 10 4 cells/well to 156 cells/well were used with a constant 10 4 irradiated patient PBMC stimulators. Cells were plated in medium containing 10 U/ml rIL-2 and were Outcomes incubated undisturbed at 37°C in a well-humidified atmosphere of 5% CO 2 until day 7 at which time the wells were Acute GVHD was defined as moderate (grade 2) to severe washed to remove IL-2 and were restimulated with (grades 3-4) and chronic GVHD was classified as limited irradiated (6 cGy) BLCL at 5 × 10 4 per well from the origor extensive using criteria previously described. 32 Patients inal stimulator in medium not containing IL-2. Cell-free surviving more than 21 days with engraftment were consupernatant was collected 24 h later and was assessed for sidered at risk for acute GVHD and those surviving у100 IL-2 content using an IL-2 sensitive murine T cell clone, days were at risk for chronic GVHD. Hematological relapse 9.12, 30 by a MTT dye reduction assay. This assay primarily was evaluated in patients with malignant disease using standiffers from the procedure which is sensitive to mHA difdard criteria. ferences in that a shorter incubation period of 7 days vs 14 days is used and BLCL restimulation is at 5 × 10 4 /well vs 10 5 /well. 31 Responder and stimulator controls and data analysis were performed as described above for CTLp.
Donor responder cells primed to patient PBMC failed to
Statistical methods produce IL-2 in response to 24 h incubation with donor BLCL, indicating that EBV antigens were not being recog-LDA frequency determinations were performed by the nized in this assay. A standard dilution curve of IL-2 from method of 2 minimization as described by Taswell. 33 Total 20 to 0.3 U/ml was included with each IL-2 assay. HTLp clonable T cell LDA frequency estimates were corrected were assessed in 46 of the 77 pairs included in the study, for cloning efficiency as described. 25 A one-way analysis 10 additional assays were excluded from analysis due to of variance (ANOVA) was used to assess the association of failure to meet control criteria. The lower detection limit CTLp and HTLp frequency with disparity. Kaplan-Meier of the LDA was 1:200 000. Frequency estimates below this estimates of acute GVHD, chronic GVHD, relapse and surlevel were considered negative.
vival by tertiles were calculated. The log-rank test was used for univariate comparisons. Cox regression model building Blocking studies was done by entering the log of the cell frequency or dose as a continuous variable into each model. For other variThe specificity of the CTL generated in the LDA assays ables a forward stepwise selection procedure was used with was assessed by collecting cells from extra wells not used in the frequency analysis that were plated at the highest a 0.1 significance level for inclusion of variables.
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Results
In three cases the only patient unique disparity was detected by IEF, and in two of these three cases CTLp were measurable. These involved recognition of HLA-A2. 1 (Figure 1 ). For this purpose only disparity however, in each case there were additional class I or class at HLA-A, -B, -DRB1 or -DQB1 was considered. For II differences detected by serology or oligotyping. Blocking CTLp frequencies, the differences between the groups were studies were performed in four cases ( Table 2 ). The cells significant by ANOVA at P = 0.0001 and for HTLp the expanded from the LDA culture of UPN 565 were highly differences were significant at P = 0.037. The frequency of reactive to patient targets (75% lysis at an effector to target CTLp and HTLp increased with the number of disparate cell ratio of 10:1). Although blocking by the class I antiantigens.
bodies was weak in this case, there was no blocking of cytotoxicity using antibodies to class II, DR, DQ or DP (not shown). Studies on UPN 652 and UPN 707 were consistent with recognition of the IEF detected variant. A summary of the IEF detected differences, the associated CTLp frequency and the blocking studies are presented in Table 2 .
Effect of HLA locus on induction of CTLp and HTLp
We assessed the data to determine if the two assays were capable of distinguishing differences based on the locus at which disparity occurred. For this purpose we considered known serological differences in HLA-C as well as unidentified HLA-C products (C locus blanks), and differences at HLA-DRB3, -DRB4 or -DRB5. CTL precursor frequencies were low (Ͻ10 cells/10 6 PBMC) or undetectable in most cases where no disparity was identified. Most HTLp frequencies were Ͻ100/10 6 PBMC in this group. However, in one case a HTLp frequency of 1:2.666 (375/10 6 PBMC) along with a CTLp frequency of 1:200 000 (5/10 6 PBMC) was detected in the absence of known disparity. Blocking studies using class II-and class I-specific MoAb showed 56% blocking by the HLA-DP antibody B7/21, and Ͻ20% blocking by L243 (anti-HLA-DR) or 1A3 (anti-HLA-DQ) with no blocking by W6/32 or 4E, suggesting that a HLA-DP difference was recognized in this donor/recipient pair. HLA-C was defined by serology in our patient series leaving the likelihood that many undetected differences existed, especially when HLA-C locus products were not identified.
14, 35, 36 For the CTLp assay, four cases with high reactivity (Ͼ1:55 000 or 18/10 6 ) were seen in pairs with a defined or potential HLA-C locus difference. However, seven pairs in which there was a serologically defined patient unique HLA-C locus difference CTLp were very low or undetected. HTLp were also higher in the group with potential HLA-C locus differences, however, the difference between no disparity and possible HLA-C locus disparity was not significant for either CTL or HTL using Student's t-test.
The CTLp assay appeared to be a sensitive indicator of HTLp assay appears to detect most class I differences and 1 = 25 ± 6, 2 = 44 ± 12, у3 = 127 ± 35. For HTLp the data were: 0 = 68 ± 27, 1 = 235 ± 88, 2 = 71 ± 27, у3 = 377 ± 246.
all tested HLA-DRB1 differences. Three HTLp assays were performed in which the only known donor/host disparity The association of CTLp or HTLp frequency or dose and with severe acute GVHD was lost after adjustment for other was a class II difference other than HLA-DRB1. Only one of the three assays was reactive, and that involved a differsignificant covariables which included the number of HLA disparities and the year of transplant. However, there was ence at HLA-DQB. The two cases in which DRB3 or DRB5 represented the only known locus of differences, the an association of borderline significance between HTLp frequencies and the probability of chronic GVHD in models HTLp assay was non-reactive. The highest precursor frequencies measured in both assays involved joint class I and adjusted for the number of HLA disparities (Table 4) . Neither CTLp nor HTLp were associated with the risk of HLA-DRB1 differences (Figure 2) .
relapse. The risk of death increased with each log increase of CTLp and HTLp frequencies (RR = 1.7 P = 0.03; Univariate analysis of outcomes RR = 1.6 P = 0.07) adjusted for CMV status and donor age (Table 5 ). Neither frequency, nor estimated cell dose of The CTLp and HTLp frequency data were stratified into tertiles to represent low, intermediate and high precursor either alloreactive population was found to predict for grades 2-4 acute GVHD in multivariate analysis (not frequencies. The Kaplan-Meier probability estimates of acute GVHD, chronic GVHD, relapse at 2 years and surshown). vival at 2 years are shown in Table 3 . Increasing CTLp and HTLp frequency was significantly associated with survival, and increasing CTLp frequency was associated with the Discussion probability of severe acute GVHD. Increasing frequencies of both precursors were associated with a higher probability Cellular assays of CTL and HTL precursor frequencies are thought to reflect the presence of known as well as of grades 2-4 GVHD (not shown), chronic GVHD and relapse but these associations did not reach significance.
unknown HLA disparity. 4, 5, 17 HLA disparity clearly affects transplant outcome but the type or degree of disparity that All of the patients in the study received TCD marrow grafts for which an estimate of the infused T cell dose was can be tolerated is not well understood. The extent to which quantitative assays of alloreactive potential between donor known, 25 therefore we reanalyzed the data based on the estimated dose/kg of CTLp and HTLp. The results were and host can detect disparity and be used to predict graft outcome was the focus of this study. Previous reports by similar to the frequency analysis showing an association of CTLp and HTLp with survival, and an association of CTLp several groups using only the CTLp assay have indicated that the frequency of host-reactive CTLp in the donor circuwith severe acute GVHD as well as a borderline significant (P = 0.03) association of CTLp/kg with chronic GVHD lation at the time of transplant was predictive of acute GVHD. 17, 19, 20 Other groups failed to confirm this find-(not shown).
ing, 18,37,38 but did report an association of CTLp precursor frequency with survival.
18,37 These studies differed in the Multivariate analysis of outcomes types of patients studied, in some cases being restricted to only presumably matched unrelated donor/recipient pairs, Multiple variables affect graft outcome. In order to adjust for other important covariates we performed Cox prothe type of transplant administered, as well as the combination of ex vivo or in vivo GVHD prophylaxis used. Most portional hazards regression analysis. Results are shown as an increase in the relative risk of the outcome studied per reports consisted of relatively few patients (10-40 patients) and analysis of the data did not consider other factors which log increase in cell dose or cell frequency. The results are presented in Table 4 and Table 5 . might affect outcome. Our patients received transplants CTLp low represents only assays below the limit of detection (Ͻ1:400 000), CTLp middle = 1:387 000-1:58 800, CTLp high = 1:55 400-1:4300. For HTLp the lowest tertile represents assays from undetected (Ͻ1:200 000) to 1:63 000, HTLp middle = 1:46 300-1:11 900, and HTLp high = 1:10 500-1:900. Relapse and survival estimates are at year two. The log rank test was used to determine if there were significant differences between the strata. (49%), the incidence of GVHD was relatively low in our series, with only 16% experiencing severe grades 3-4 acute GVHD compared to Ͼ50% of patients receiving non-TCD not elicit a cellular response. Both CTLp and HTLp assays detected differences in HLA-A and HLA-B locus antigens grafts from matched unrelated donors. 2, 3 Because the number of T cells administered with the graft was known in our defined by serology and by IEF. The HTLp assay appeared to be more sensitive to HLA-DRB1 differences than the patient group, we analyzed the data based on alloreactive precursor frequency and the estimated dose of alloreactive CTLp assay. Neither assay detected class II differences restricted to DRB3, DRB4 or DRB5 when tested in isolated precursors infused with the marrow.
We found an association between alloreactive precursor cases and both assays were reactive in the one patient tested with an isolated HLA-DQ difference. When only HLA-A, frequency and known HLA disparity but not in every case. There was reactivity in some cellular assays without known HLA-B, HLA-DRB1 and HLA-DQB were considered, there was a correlation between the number of HLA disdisparity, and less often disparity was detected which did association of CTLp with severe acute GVHD was lost after adjustment for HLA disparity. However, HTLp frequency remained associated with the risk of chronic GVHD and parities detected and the frequency estimates for both assays.
both assays were associated with survival, but not with relapse in models considering other significant risk factors. CTLp (16 of 38) and/or HTLp (16 of 22) assays were reactive to varying degrees in some donor/recipient pairs
The findings indicate that these assays do provide an additional measure of outcome beyond the presence of without identified HLA disparity. Blocking studies showed CTL recognition of HLA-DP in one case with a weakly other known risk factors. The associations of CTLp and HTLp with outcome did reactive CTLp but strongly reactive HTLp assay, indicating that in some circumstances HLA-DP may induce a cytolytic not differ markedly when the estimated dose of precursors infused with the marrow graft was considered in place of T cell response. However, given the number of negative CTLp assays (27 of 76 performed) and the very high probthe frequency estimate. Clearly T cell dose does affect transplant outcome as evidenced by the decreased risk of ability of HLA-DP disparity in unrelated donor/recipient pairs, 15 it seems unlikely that HLA-DP differences are well acute GVHD in recipients of unrelated or HLA disparate related T cell-depleted marrow. 3, 21, 42 We have recently recognized in the CTLp assay. Disparity at HLA-DP may well account for some of the unexplained reactivity in the assessed the role of T cell dose on graft outcome in 273 recipients of marrow T cell-depleted using T 10 B 9 and found HTLp assay. HLA-C was defined at the level of serology in our patient group. In part due to the poor expression of an association of total clonable T cells and TCR␣␤ + T cells with acute GVHD, but only in recipients of marrow from HLA-C at the cell surface, serology detects only a fraction of the polymorphism at this locus and has a higher degree an related donor. 43 The failure to find an association of T cell dose in recipients of unrelated donor grafts may indiof discrepancy.
9,36 CTL can recognize both defined and serologically undefined HLA-C differences. 35, 39 However, cate that within the dose range administered with marrow TCD with T 10 B 9 , the alloreactive potential of the cells primin six of nine pairs for whom a serologic difference at HLA-C was identified, the CTLp assay was nonreactive arily determines GVHD risk. In support of this hypothesis, no patient in the group that had undetectable CTLp or indicating that HLA-C was not well recognized by our CTLp assay. In contrast, six of seven HTLp assays perforHTLp experienced severe acute GVHD. Within the positive assays there was no clear association of frequency or dose med in patients with only a defined HLA-C locus difference were reactive, suggesting this assay may also be more with GVHD risk in either univariate or multivariate analysis. The alloreactive precursor frequencies were determined sensitive to HLA-C locus disparity. HLA sequencing studies targeting donor/recipient pairs in which CTL or HTL using donor peripheral blood mononuclear cells, whereas, TCD donor bone marrow was used as the source of stem reactivity was detected are in progress to address definitively the possibility of additional disparity. Preliminary cells. It may be that the frequency of alloreactive T cells contained in the marrow does not directly reflect the periphsequencing data from four donor/recipient pairs included in this study indicate that some cellular reactivity can be eral population, or it may be that our method of TCD selectively removes or spares, alloreactive precursors. CTLp explained by HLA-A or HLA-B locus differences not detected by serology or IEF.
frequency in a given donor/recipient pair may also be influenced by prior viral infections which may markedly The HTLp assay can be made sensitive to mHA differences by prolonging the period of time in culture and using expand viral reactive CTL crossreactive to HLA alloantigens as demonstrated by the enhanced response to HLAa higher number of cells to stimulate IL-2 production than the method we employed. 31, 40, 41 Preliminary assessment of B * 4402 in HLA-B8 + individuals exposed to Epstein-Barr virus. 44 The usefulness of cellular assays of pretransplant our HTLp assay in three matched sibling donor/recipient pairs each of whom experienced у2 grade acute GVHD alloreactivity to predict GVHD and other graft outcomes in
